4-CLASS RESISTANCE IS RARE IN TREATMENT EXPERIENCED PATIENTS ACROSS EUROPE

Maurizio Zazzi1, Anne-Mieke Vandamme2, Barbara Rossetti3, Massimiliano Fabbiani3, Francesca Incardona4,10, Kristof Thys2, Ana Abecasis5, Carole Devaux6, Rolf Kaiser7, Anders Sönnerborg8, Giuseppe Pasculli9, Jurgen Vercauteren2

for the EuResist Network study group.

1University of Siena, Siena, Italy, 2Katholieke University Leuven, Leuven, Belgium, 3Siena University Hospital, Siena, Italy, 4-10PRO, Roma, Italy, 5Instituto de Higiene e Medicina Tropical Universidade NOVA de Lisboa, Lisboa, Portugal, 6Centre Hospitalier de Luxembourg, Luxembourg, Luxembourg, 7University of Cologne, Cologne, Germany, 8Karolinska Institute, Stockholm, Sweden, 9La Sapienza University, Rome, Italy, 10EuResist Network, Rome, Italy

BACKGROUND

While most HIV-1 patients starting antiretroviral therapy (ART) in recent years achieve and maintain undetectable viral load, patients with a long ART history and failure of multiple therapy lines may have accumulated substantial drug resistance, challenging the possibility for virus control both at individual and population level. However, the prevalence of patients harboring virus with resistance to the four main drug classes (4CR) is largely unknown.

METHODS

From the EuResist database, we selected treated patients with protease, reverse transcriptase and integrase genotype information available at one or more time points in 2008-2019. HIV-1 sequences were interpreted by the Stanford HIVdb 8.8 algorithm. Cumulative resistance scores were generated at each sequencing time point and 4CR was defined as high-level resistance to at least one drug in each of the four classes, considering 3TC, FTC, ABC, TDF and AZT as NRTIs; NVP, EFV, ETR, RPV and DOR as NNRTIs; ATV, DRV, LPV and SQV as boosted PIs; RAL, EVG, DTG as INSTIs. The frequency of 4CR at each calendar year was estimated as the number of unique patients with at least one sample, up to that year. The factors associated with the development of 4CR were statistically determined by Chi-square tests, Wilcoxon rank sum tests and univariate and multivariate logistic regression in RStudio. The table on the right shows factors univariately or multivariately associated (2008-2019) indicated a significant decrease over time (p <0.001; see main graph above). The cumulative prevalence of 4CR over the last 12 years with respect to database source, region of origin of participants and HIV-1 subtype is shown in the graphs below. The cumulative prevalence of 4CR over the last 12 years (2008-2019) indicated a significant decrease over time (p <0.001; see main graph above). The table on the right shows factors univariately or multivariately associated with 4CR.

RESULTS

3414 distinct patients matched the inclusion criteria contributing 4594 genotype data from the EuResist database (January 2020 update), with 78.5%, 14.8% and 6.7% of patients contributing genotypic data at one, two and more than two time points. Over time, the 4CR status was reached by 85 (2.5%) patients only. The distribution of data from the EuResist database (January 2020 update), with 78.5%, 14.8% and 6.7% of patients contributing genotypic data at one, two and more than two time points. Over time, the 4CR status was reached by 85 (2.5%) patients only. The distribution of data

CONCLUSION

In a large population of patients across Europe with complete HIV-1 genotype information, the prevalence of 4CR appears to be relatively low and possibly declining over recent years. Significant predictors of 4CR at multivariable analysis included lower nadir CD4 cell counts, a higher number of treatment failures and previous exposure to mono/dual therapy (borderline significance). Continuous surveillance of this challenging population is warranted to provide effective treatment at the individual level and define factors predicting accumulation of resistance over time.

Funding for this study was provided by ViiV Healthcare. The authors are solely responsible for final content and interpretation.